Clene (CLNN) vs iBio (IBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Clene (CLNN) over the past year, gaining 5.7% versus a loss of 58.8%. Over five years, CLNN leads with a -96.9% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($59.2 million vs $55.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | IBIO |
|---|---|---|
| Share price | $3.88 | $0.92 |
| Market cap | $55.15M | $59.16M |
| 1-day change | -1.02% | -8.91% |
| YTD return | -33.90% | -52.33% |
| 1-year return | -58.81% | +5.75% |
| 5-year return | -96.86% | -99.80% |
| EPS (TTM) | $-3.52 | $-0.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.50 | $3.82 |
| 52-week low | $3.25 | $0.78 |
| Distance from 52-week high | -71.26% | -75.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +729.90% | +518.48% |
| Average volume | 100.21K | 727.93K |
| Shares outstanding | 14.21M | 64.31M |
| Employees | 76 | 23 |
| Sector | Consumer Defensive | Healthcare |
| Industry | Packaged Foods | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed CLNN by 64.6 percentage points over the past year.
- The two companies sit in different sectors: Clene in Consumer Defensive and iBio in Healthcare.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Consumer Defensive · Packaged Foods · 76 employees
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Healthcare · Biotechnology · 23 employees
CLNN vs IBIO FAQ
Which is bigger, Clene or iBio?
iBio (IBIO) is larger, with a market capitalization of $59.16M compared with $55.15M for Clene (CLNN).
Which stock has performed better over the past year, CLNN or IBIO?
IBIO returned +5.75% over the past 12 months, compared with -58.81% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and iBio in the same industry?
No. Clene is in the Consumer Defensive sector, while iBio is in Healthcare.